Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ZLJ
|
|||
| Former ID |
DNC008561
|
|||
| Drug Name |
LOSOXANTRONE
|
|||
| Synonyms |
Losoxantrone; 88303-60-0; Losoxantrone [INN:BAN]; Bis-alkylamino anthrapyrazole; UNII-47KPH00809; CHEMBL83520; 47KPH00809; CI-941; bianthrazole; C22H27N5O4; DuP-941; DUP 941; Anthra(1,9-cd)pyrazol-6(2H)-one, 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)-; AC1Q6OLU; AC1L2HG1; SCHEMBL61319; DTXSID60236949; ZINC1583637; BDBM50240660; NCI60_003246; LS-178051; 33933-EP2311453A1; 33933-EP2308855A1; 33933-EP2275420A1; 33933-EP2270008A1; 33933-EP2298765A1; 33933-EP2298764A1; 33933-EP2292617A1
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H27N5O4
|
|||
| Canonical SMILES |
C1=CC2=C(C(=C1)O)C(=O)C3=C(C=CC4=C3C2=NN4CCNCCO)NCCNCCO
|
|||
| InChI |
1S/C22H27N5O4/c28-12-9-23-6-7-25-15-4-5-16-20-19(15)22(31)18-14(2-1-3-17(18)30)21(20)26-27(16)11-8-24-10-13-29/h1-5,23-25,28-30H,6-13H2
|
|||
| InChIKey |
YROQEQPFUCPDCP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 88303-60-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II (TOP2) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000754) | |||
| REF 2 | A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.